Pharmacotherapics Advice in Guidelines for COVID-19

Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhang-Ren, Zhou, Ying, Liu, Jin, Peng, Hong-Wei, Zhou, Jian, Zhong, Hai-Li, Liu, Li-Li, Lai, Ming-Fang, Wei, Xiao-Hua, Wen, Jin-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327107/
https://www.ncbi.nlm.nih.gov/pubmed/32670066
http://dx.doi.org/10.3389/fphar.2020.00950
Descripción
Sumario:Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.

Ejemplares similares